Studies showed that the combined therapy of anlotinib and ICIs in a neuroblastoma work, by promoting tumor vascular normalization at least in part via CD4 T cells, reprogrammed immunosuppressive TME to immunostimulatory TME, prolonging the period of vascular normalization and effectively preventing systemic immunosuppression (40). The gene discussed is CD4; the disease is neuroblastoma.